Chargement en cours...
Real world experience on treatment, outcome and toxicity of crizotinib in patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer
BACKGROUND: Crizotinib has been the standard treatment for patients with anaplastic lymphoma kinase (ALK)-rearranged advanced non-small cell lung cancer (NSCLC). It demonstrated superior progression-free survival (PFS) and higher objective response rates (ORRs) vs. chemotherapy in previously treated...
Enregistré dans:
| Publié dans: | J Thorac Dis |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
AME Publishing Company
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6790458/ https://ncbi.nlm.nih.gov/pubmed/31656659 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2019.09.15 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|